Abstract: This invention discloses an injectable nanocomposite gel composition and the method of making the composition. The composition is composed of amphiphilic alginate nanoparticle, gel stabilizer, gel crosslinker, and gel structural modifiers. The nanocomposite gel can be manufactured into a form of highly-viscous gel or a solid-like gel, used as a vehicle to carry and deliver pharmaceutically active ingredients with high drug load via injection administration for medical uses.

Abstract: The present disclosure provides a dual-drag-containing nanoparticle, in which a first antiviral drag, such as remdesivir and a second antiviral drag are co-encapsulated and co-delivered by the nanoparticle, said nanoparticle comprising an alginate-oleic acid particle. The disclosure also relates to the therapeutic use of the nanoparticle in treating viral infections, such as SARS-CoV-2.

Abstract: A substance delivery mask includes a body, an exhaling valve, an inhaled valve, and a fog module. The fog module comprises a controlling module, a container, and an atomizer. The controlling module is disposed on the body. The container is disposed on the controlling module, the container is storing a mixed liquid, and the mixed liquid includes water and a plurality of nanoparticles. The atomizer is disposed on the container, the atomizer is used to atomize the water of the mixed liquid to form fog particles, and the fog particles are wrapped several of the nanoparticles respectively. The substance delivery mask can encapsulate the water-soluble or water-insoluble medicines, or nutritional products in the fog particles generated from the atomizer. The present invention can deliver medicine, nutritional products or vaccines by inhalation or oral.

Abstract: The present invention provides a new type of hydrophobically -modified sodium alginate, which is synthesized by alginate and oleic acid linked with a spacer. The AGO macromolecule as obtained therefrom is amphiphilic and has clinically-accessible molecular size, and anti- cancer activity. The AGO nanoparticle formed therefrom shows excellent structural stability, colloidal stability, and biocompatibility in-vitro and in-vivo, and is expected to be useful in biomedical area, for example, used as a drug delivery system.

Abstract: A nanodrug particle includes alginate and a camptothecin compound. The camptothecin compound is grafted onto the alginate, and the alginate and the camptothecin compound self-assemble and form a nanosphere. The disclosure also provides a method for preparing a nanodrug particle; the method includes: modifying alginate to form alginate having amine groups; modifying a camptothecin compound to form a camptothecin compound having a carboxyl group; forming a camptothecin-alginate polymer by reacting the alginate having amine groups with the camptothecin compound having a carboxyl group, wherein the camptothecin-alginate polymer self-assembles in an aqueous solution and forms a nanosphere.

Abstract: The present invention discloses a composite-type nano-vaccine particle, which comprises an active ingredient selected from spike RBD protein of COVID-19, two adjuvants as aluminium salt nanoparticle and synthetic oligonucleotides, and an amphiphilic alginate-based nanocarrier encapsulating the active ingredient and the two adjuvants. The composite-type nano-vaccine particle has a particle size ranging from 300 nm to 1400 nm in diameter.

Abstract: The present invention provides a virus collection matrix, including: a porous gel or fibrous structure formed by a positively charged polymer material; and a plurality of ACE 2 receptors. The plurality of ACE 2 receptors are negatively charged, and distributed and covered on the surface of the porous gel or fibrous structure. The whole virus collection matrix is positively charged.

Abstract: The present invention relates to a drug composition and method for treating breast cancer, and more specifically, to use carboxymethyl-hexanoyl chitosan (CHC) to co-encapsulate a heat shock protein 90 (HSP90) inhibitor and a hydrophobic drug. The two drugs can be co-encapsulated with high encapsulation efficiency and co-delivered to breast cancerous cells, and achieve a synergistic efficacy to kill the cancerous cells.

Abstract: An amphiphilic polymer, an amphiphilic polymer manufacturing method, a contact lens material including the amphiphilic polymer, and contact lens manufacturing method are provided. The amphiphilic polymer includes poly(dimethylsiloxane) and amphiphilic chitosan bonded to the same. The contact lens material includes the amphiphilic polymer. The amphiphilic polymer manufacturing method includes providing a poly(dimethylsiloxane), providing an amphiphilic chitosan, and bonding the amphiphilic chitosan to the poly(dimethylsiloxane).

Abstract: Disclosed herein is a ganetespib-containing particle, which includes an active ingredient selected from ganetespib, a pharmaceutically acceptable salt of ganetespib, and a combination thereof, and an amphiphilic chitosan-based carrier carrying the active ingredient. Also disclosed herein are a pharmaceutical composition including the ganetespib-containing particle, and use of such pharmaceutical composition in treating cancer.

Abstract: An amphiphilic polymer, an amphiphilic polymer manufacturing method, use of an amphiphilic polymer as a contact lens material, and a contact lens material including the same are provided. The amphiphilic polymer includes amino-conjugated mono-HEMA (mHEMA-NH2) and amphiphilic chitosan bonded to the same. The amphiphilic polymer manufacturing method includes providing a mHEMA-NH2, providing an amphiphilic chitosan, and bonding the mHEMA-NH2 to the amphiphilic chitosan.

Abstract: A manufacturing method of amphiphilic macromolecules is provided. The method includes: reacting the first acrylic acid with N,N?-carbonyldiimidazole to obtain a modified acrylic acid derivative; and reacting the modified acrylic acid derivative with the siloxane derivative to obtain amphiphilic macromolecules. Wherein, the terminal of the first acrylic acid has a hydroxyl group. Wherein, the siloxane derivative is a hydroxyl-terminated, acrylamide-terminated, epoxy-terminated or amine-terminated polysiloxane molecule.

Abstract: Disclosed herein is a ganetespib-containing particle, which includes an active ingredient selected from ganetespib, a pharmaceutically acceptable salt of ganetespib, and a combination thereof, and an amphiphilic chitosan-based carrier carrying the active ingredient. Also disclosed herein are a pharmaceutical composition including the ganetespib-containing particle, and use of such pharmaceutical composition in treating cancer.

Abstract: An amphiphilic polymer, an amphiphilic polymer manufacturing method, use of an amphiphilic polymer as a contact lens material, and a contact lens material including the same are provided. The amphiphilic polymer includes amino-conjugated mono-HEMA (mHEMA-NH2) and amphiphilic chitosan bonded to the same. The amphiphilic polymer manufacturing method includes providing a mHEMA-NH2, providing an amphiphilic chitosan, and bonding the mHEMA-NH2 to the amphiphilic chitosan.

Abstract: A manufacturing method of amphiphilic macromolecules is provided. The method includes: reacting the first acrylic acid with N,N?-carbonyldiimidazole to obtain a modified acrylic acid derivative; and reacting the modified acrylic acid derivative with the siloxane derivative to obtain amphiphilic macromolecules. Wherein, the terminal of the first acrylic acid has a hydroxyl group. Wherein, the siloxane derivative is a hydroxyl-terminated, acrylamide-terminated, epoxy-terminated or amine-terminated polysiloxane molecule.

Abstract: An amphiphilic polymer, an amphiphilic polymer manufacturing method, a contact lens material including the amphiphilic polymer, and contact lens manufacturing method are provided. The amphiphilic polymer includes poly(dimethylsiloxane) and amphiphilic chitosan bonded to the same. The contact lens material includes the amphiphilic polymer. The amphiphilic polymer manufacturing method includes providing a poly(dimethylsiloxane), providing an amphiphilic chitosan, and bonding the amphiphilic chitosan to the poly(dimethylsiloxane).

Abstract: A nanocomposite, a preparation method thereof and a method for treating cancer using the same are provided. The preparation method includes: mixing a first solution including an amphiphilic chitosan and a second solution including anti-cancer components, wherein the anti-cancer components includes gemcitabine, curcumin, the derivatives and combinations thereof; forming a nanoparticle encapsulating the anti-cancer component by a self-assembling process of the amphiphilic chitosan, and binding the nanoparticle with a targeting molecule having specificity to a cancer so as to obtain a nanocomposite. When dissolving the nanocomposite of the present invention after drying into water phase, the nanocomposite still has the same morphology and characteristic before it is dried, so it is convenient for storage and delivery. Additionally, the preferable ratio of gemcitabine and demethoxycurcumin will bring a synergistic effect on cancer therapy.

Abstract: A self-assembled nanostructure including an amphiphilic chitosan and a contrast agent compound is provided. The contrast agent compound is grafted to the amphiphilic chitosan. The chemical bonding between the amphiphilic chitosan and the contrast agent compound has a synergistic effect to further improve the contrasting ability of the contrast agent compound.

Abstract: The present disclosure herein provides a compound prescription colloidal eyedrop gel. The compound prescription colloidal eyedrop gel includes a plurality of carboxymethyl-hexanoyl chitosan (CHC) micelles, a basic structural stabilizer connecting the plurality of CHC micelles, a first drug inside the CHC micelle, and a second drug outside the CHC micelle.

Abstract: The present disclosure herein provides a compound prescription colloidal eyedrop gel. The compound prescription colloidal eyedrop gel includes a plurality of carboxymethyl-hexanoyl chitosan (CHC) micelles, a basic structural stabilizer connecting the plurality of CHC micelles, a first drug inside the CHC micelle, and a second drug outside the CHC micelle.